Sale
Massive Discounts! Up to 30% OFF on reports🎉

Beri Beri Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: March 2024 || SKU: PH5097
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Download Free Sample

Beri Beri Treatment Market is Segmented By Type (Wet Beri Beri, Dry Beri Beri), By Drug Type (Branded, Generics), By End-User (Hospitals, Specialty Clinics, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.

 

Beri Beri Treatment Market is estimated to reach at a high CAGR 7% during the forecast period (2024-2031).

Vitamin B1 deficiency is a disease in which the body does not have enough of the vitamin (thiamin). A poor diet or alcoholism most commonly brings on beriberi. Loss of appetite, weakness, limb pain, shortness of breath, and swollen feet or legs are some of the symptoms.

As per DataM Intelligence, Beri Beri Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Beri Beri Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Beri Beri Treatment Market in the United States and Canada produces the utmost share. Whereas the European Beri Beri Treatment Market is projected to continue its presence globally during the period of 2024-2031.

Beri Beri Treatment Market Scope

Metrics

Details

Market CAGR

7%

Segments Covered

By Type, By Drug Type, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

 

Beri Beri Treatment Market Dynamics

The factors influencing the global beri beri treatment market are the increasing research and development and the growing prevalence of thiamine deficiency.

The increasing research and development is expected to drive the market growth in the forecast period

Edema, breathlessness, muscle weakness, and beriberi, a sheep-like gait pattern, are all symptoms of thiamine deficiency. Thiamine is a water-soluble vitamin that cannot be stored in significant quantities. Surgery, fasting, strenuous activity, fever, sepsis, pregnancy, breastfeeding, adolescent growth, and anorexia increase thiamine requirements. Acute or fulminant beriberi can result from an increased requirement for thiamine or a decrease in thiamine consumption after a gastrectomy, with aging patients being more susceptible. Beriberi can develop many years after gastrectomy and go unnoticed by doctors, resulting in treatment delays. It's critical to recognize and treat beriberi as soon as possible, as well as a rule out other possible diagnoses. Beriberi is a nutritional complication of gastric surgery that has life-threatening clinical implications. Because thiamine is absorbed in the duodenum and proximal jejunum, patients with a total gastrectomy, Billroth II gastrectomy, or Roux-en-Y diversion are at an increased risk. Beriberi has also been reported after laparoscopic sleeve gastrectomy, gastroplasty, and laparoscopic adjustable gastric banding. After upper gastrointestinal surgery, patients frequently have subclinical thiamine deficiency. Thiamine deficiency causes glucose metabolism problems, reduced oxygen delivery by red blood cells, cardiac dysfunction, axonopathy, neurotransmission failure, and neuron death. Moreover, for men and women, the Recommended Dietary Intake (RDI) of oral thiamine is 1.2 mg and 1.1 mg, respectively, and the daily Estimated Average Requirement (EAR) is 1.0 mg and 0.9 mg. Sensorimotor peripheral neuropathy, Wernicke encephalopathy, Korsakoff psychosis (dry beriberi), cardiac failure, edema, and arrhythmia are symptoms of thiamine deficiency (wet beriberi).

The side effects associated with beriberi treatment are expected to hamper the market growth

The side effects associated with thiamine are severe allergic reaction to heat (anaphylaxis), discoloration of the skin, sweating \srestlessness, hives with rapid skin swelling and itching, inflammation of the lungs (pulmonary edema), weakness, nausea throat constriction.

There are no known serious interactions between thiamine and other medications. The following are examples of thiamine interactions moderate azithromycin \sclarithromycin, erythromycin lactobionate, erythromycin stearate,  erythromycin base erythromycin ethylsuccinate, and roxithromycin. At least 69 different drugs have mild interactions with thiamine. Hence, the side effects and interactions associated with thiamine are expected to hamper market growth.

COVID-19 Impact Analysis

Thiamine as adjunctive therapy may improve survival in COVID-19 patients who are critically ill. Additionally, it was linked to a reduced risk of thrombosis. Systemic thiamine administration may be considered part of COVID-19 management during ICU admission. The role of thiamine in COVID-19 patients is still unknown; however, it has been studied extensively in critically ill patients. Moskowitz et al. found that thiamine was linked to significantly lower lactate levels, serum creatinine, and a possible reduction in 30-day mortality in a randomized controlled trial. In addition, thiamine administration within 24 hours was linked to improved lactic acid clearance and lower 28-day mortality in critically ill patients with septic shock. Hence, the increasing demand for thiamine during covid-19 is expected to positively impact the market.

Beri Beri Treatment Market Segment Analysis

Wet Beriberi segment is expected to dominate the market growth

Thiamine deficiency with cardiovascular involvement is referred to as wet beriberi. There are three stages to the chronic form of wet beriberi. Peripheral vasodilation occurs in the first stage, resulting in a high cardiac output state. This causes salt and water retention in the kidneys, mediated by the renin-angiotensin-aldosterone system. The kidneys detect a relative volume loss as the vasodilation progresses and respond by conserving salt. Fluid is absorbed into the circulatory system as a result of salt retention. Edema of the dependent extremities occurs as a result of fluid overload.

Acute fulminant cardiovascular beriberi, also known as Shoshin beriberi, is a faster form of wet beriberi. The heart is the most commonly injured organ, and rapid deterioration results from the heart muscle's inability to meet the body's demands due to its injury. Edema may not be present in this case. Instead, cyanosis of the hands and feet, tachycardia, dilated neck veins, restlessness, and anxiety are experienced. Because systemic vasoconstriction is restored before the heart muscle recovers, thiamine treatment causes low-output cardiac failure. Vitamin B1 therapy can help with the diagnosis and treatment of wet beriberi. It is widely accepted that patients suspected of having thiamine deficiency should receive therapeutic thiamine administration.

Beri Beri Treatment Market Geographical Analysis

North America region is expected to hold the largest market share in the global beri beri treatment market

Due to high healthcare costs and high-quality medical facilities, the vast majority of the population is covered by insurance. The presence of key players in the market is expected to drive market growth. For instance, the company Fresenius Kabi USA’s thiamine hydrochloride injection, USP, is effective for treating berberi.

Beri Beri Treatment Market Competitive Landscape

The global beri beri treatment market is moderately competitive. Some of the key players in the market are Fresenius Kabi USA, LLC, GlaxoSmithKline plc, Parex Pharmaceuticals Pvt. Ltd., Solgar, EZ Melts, Bulk Supplements, DSM, AdvaCare Pharma.

Fresenius Kabi USA

Overview: Fresenius Kabi is a global healthcare company specializing in infusion, transfusion, and clinical nutrition medicines and technologies. The company has headquarters in  Illinois, United States, founded in 1912.

Product Portfolio: Thiamine hydrochloride injection, USP is a sterile solution of thiaminehydrocholride in water for injection for intramuscular (IM) or slow intravenous (IV) administration. It is effective for the treatment of berberi.

Buy this report
Single User
$4350$3480
Multiple User
$4850$3880
Enterprise User
$7850$6280
Proceed to Buy
  Get Free Sample
  Request new version
  Customize Sample
  Demo Full Report
FAQ’s

  • Tay-Sachs Disease Treatment Market is expected to grow at a CAGR of 7% during the forecasting period 2024-2031.

  • North America region Controls the Beri Beri Treatment Market during 2024-2031.

  • Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

  • The global beri beri treatment market is moderately competitive. Some of the key players in the market are Fresenius Kabi USA, LLC, GlaxoSmithKline plc, Parex Pharmaceuticals Pvt. Ltd., Solgar, EZ Melts, Bulk Supplements, DSM, AdvaCare Pharma.